Adalimumab in the treatment of refractory adult-onset Still's disease

Int J Rheum Dis. 2017 Nov;20(11):1798-1799. doi: 10.1111/1756-185X.12421. Epub 2014 Jun 21.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adalimumab / therapeutic use*
  • Aged
  • Anti-Inflammatory Agents / therapeutic use*
  • Humans
  • Male
  • Remission Induction
  • Still's Disease, Adult-Onset / diagnosis
  • Still's Disease, Adult-Onset / drug therapy*
  • Still's Disease, Adult-Onset / immunology
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Anti-Inflammatory Agents
  • Tumor Necrosis Factor-alpha
  • Adalimumab